Esmolol
اسمولول
❤️ Cardiovascular SystemShort-acting IV beta-blocker
Market / country: 🇺🇸 USA
Brevibloc (US)
🧮 Dose calculator
Paroxysmal supraventricular tachycardia · Regimen source: FDA Brevibloc · 2.1
- • Optional load 500 mcg/kg over 1 min, then 50 mcg/kg/min for 4 min; titrate at ≥4-min intervals by rate or BP. FDA Brevibloc · 2.1
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Severe sinus bradycardia; heart block above first degree; sick sinus syndrome; decompensated heart failure; cardiogenic shock; pulmonary hypertension; recent IV verapamil. FDA Brevibloc · 4
Formulations
- 10 mg/mL premixed bag or vial (10,000 mcg/mL) — injection 🇺🇸 USA FDA Brevibloc · 3
- 20 mg/mL double-strength bag (20,000 mcg/mL) — injection 🇺🇸 USA FDA Brevibloc · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Brevibloc · 8.1
“BREVIBLOC injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
- 🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Brevibloc · 8.3
“Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from BREVIBLOC injection, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Brevibloc · 8.4
“The safety and effectiveness of BREVIBLOC injection in pediatric patients have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Brevibloc · 8.5
“In general, dose selection for an elderly patient should usually start at the low end of the dosing range, reflecting greater frequency of decreased renal or cardiac function and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA019386
- DailyMed (FDA label)FDA Brevibloc
- MedlinePlus (NIH)❌ None
- WHO ATC/DDDC07AB09
- Darooyab (Iran)Esmolol
🇮🇷 Registered in Iran Darooyab · G-1668/Esmolol
Dosage forms with Iranian generic codes, per Darooyab.
- 06916 · ESMOLOL 100MG VIAL · ویال اسمولول ۱۰۰ میلیگرم
- 20430 · ESMOLOL 10MG VIAL · ویال اسمولول ۱۰ میلیگرم
- 01494 · ESMOLOL HCL 250/ML 10ML AMP · آمپول اسمولول هیدروکلراید ۲۵۰ / میلیلیتر ۱۰ میلیلیتر
- 52330 · ESMOLOL HYDROCHLORIDE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION PARENTERAL 2500 mg · محلول تزریقی اسمولول هیدروکلراید ۲۵۰۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Brevibloc · 3FDA Brevibloc · 2.1FDA Brevibloc · 2.2FDA Brevibloc · 4FDA Brevibloc · SPL approval / marketing categoryFDA Brevibloc · 8.1FDA Brevibloc · 8.3FDA Brevibloc · 8.4FDA Brevibloc · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1668/Esmolol
- Clinical review⚠ Unverified